Itraconazole (itraconazole): Reviews and patient testimonials

Itraconazole 10 mg/ml Oral Solution

Itraconazole oral solution is indicated:

• For the treatment of oral and/or oesophageal candidosis in HIV-positive or other immunocompromised patients.

• As prophylaxis of deep fungal infections anticipated to be susceptible to itraconazole, when standard therapy is considered inappropriate, in patients with haematological malignancy or undergoing bone marrow transplant, and who are expected to become neutropenic (i.e. < 500 cells/µl). At present there are insufficient clinical efficacy data in the prevention of aspergillosis.

Itraconazole oral solution is indicated for use in adults.

Consideration should be given to national and/or local guidance regarding the appropriate use of antifungal agents.

Itraconazole 100 mg Capsules

Itraconazole is indicated for the treatment of the following fungal infections when thought likely to be susceptible:

• Vulvovaginal candidiasis.

• Pityriasis versicolor.

• Dermatophytoses caused by organisms susceptible to itraconazole (Trichophyton spp. Microsporum spp. Epidermophyton floccosum) e.g. tinea pedis, tinea cruris, tinea corporis, tinea manuum.

• Oral candidiasis.

• Onychomycosis caused by dermatophytes and/or yeasts.

Consideration should be given to official guidance regarding the appropriate use of antifungal agents.

For further information please refer to section 5.1.

Itraconazole 100 mg Capsules, hard

Superficial mycoses

Itraconazole is indicated if external treatment is not effective or not appropriate for the treatment of the following fungal infections:

- dermatomycoses (e.g. tinea corporis, tinea cruris, tinea pedis, tinea manus)

- Pityriasis versicolor

Systemic mycoses

Itraconazole is indicated for the treatment of systemic mycoses, such as candidiasis, aspergillosis, and histoplasmosis.

Consideration should be given to official guidance on the appropriate use of antimycotic agents.

Itraconazole 100mg Capsules, hard

- Vulvovaginal candidiasis,

- Oral candidiasis

- Dermatophytoses caused by organisms susceptible to itraconazole (Trichophyton spp., Microsporum spp., Epidermophyton floccosum) e.g. tinea pedis, tinea cruris, tinea corporis, tinea manuum,

- Pityriasis versicolor,

- Onychomycoses caused by dermatophytes and/or yeasts,

- Systemic candidiasis,

- Cryptococcal infections (including cryptococcal meningitis). In immunosuppressed patients suffering from cryptococcosis and in patients with cryptococcosis of the CNS Itraconazole is indicated only if the usually recommended initial therapy seems to be inappropriate or ineffective

- Histoplasmosis.

- Aspergillosis. Itraconazole can be used to treat patients suffering from invasive aspergillosis who were found to be refractory or intolerant to Amphotericin B

- Maintenance therapy in AIDS patients to prevent relapse of underlying fungal infection who were found to be refractory or intolerant to first-line systemic anti-fungal therapy is inappropriate or has proved ineffective.

Due to PK properties, orally administered itraconazole (capsules) should not be used as the initial treatment in patients with severe life-threatening forms of systemic mycoses. Oral forms should be used as a continuation therapy, after initial treatment with i.v. itraconazole.

Consideration should be given to official guidance regarding the appropriate use of antifungal agents.

Itraconazole 10mg/ml Oral Solution

Itraconazole Oral Solution is indicated in adults:

• For the treatment of oral and/or oesophageal candidosis in HIV-positive or other immunocompromised patients.

• As prophylaxis of deep fungal infections anticipated to be susceptible to itraconazole, when standard therapy is considered inappropriate, in patients with haematological malignancy or undergoing bone marrow transplant, and who are expected to become neutropenic (ie < 500 cells/μl). At present there are insufficient clinical efficacy data in the prevention of aspergillosis.

Consideration should be given to national and/or local guidance regarding the appropriate use of antifungal agents.
Route of administration: Oral
Molecule: itraconazole